The agency released guidance for industry regarding the United Kingdom’s withdrawal from the European Union.
On May 31, 2017, the European Medicines Agency (EMA) and the European Commission published guidance on how pharmaceutical companies can prepare for Brexit. The guidance offers information on centralized procedures and other agency activities. The guidance is one in a series of guidance documents the agency plans to publish on the effects of the United Kingdom’s withdrawal from the European Union.
Specifically, the guidance answers some of the industry’s questions regarding the implication of Brexit on marketing authorizations, orphan drug designations, and pharmacovigilance. The document address concerns regarding the location of personnel, documents, and manufacturing facilities currently located in the UK.
Source: EMA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.